Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RenovoRx (RNXT) Cash & Equivalents (2024 - 2025)

Historic Cash & Equivalents for RenovoRx (RNXT) over the last 2 years, with Q3 2025 value amounting to $10.0 million.

  • RenovoRx's Cash & Equivalents rose 462.5% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 462.5%. This contributed to the annual value of $7.2 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, RenovoRx's Cash & Equivalents stood at $10.0 million, which was up 462.5% from $12.3 million recorded in Q2 2025.
  • In the past 5 years, RenovoRx's Cash & Equivalents ranged from a high of $14.6 million in Q1 2025 and a low of $4.4 million during Q1 2024